Document Detail


Therapeutic potential of n-3 polyunsaturated fatty acids in disease.
MedLine Citation:
PMID:  19535655     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The potential therapeutic benefits of supplementation with n-3 polyunsaturated fatty acids (PUFAs) in various diseases are reviewed, and the antiinflammatory actions, activity, and potential drug interactions and adverse effects of n-3 PUFAs are discussed. SUMMARY: Fish oils are an excellent source of long-chain n-3 PUFAs, such as eicosapentaenoic acid and docosahexaenoic acid. After consumption, n-3 PUFAs can be incorporated into cell membranes and reduce the amount of arachidonic acid available for the synthesis of proinflammatory eicosanoids (e.g., prostaglandins, leukotrienes). Likewise, n-3 PUFAs can also reduce the production of inflammatory cytokines, such as tumor necrosis factor alpha, interleukin-1, and interleukin-6. Considerable research has been conducted to evaluate the potential therapeutic effects of fish oils in numerous conditions, including arthritis, coronary artery disease, inflammatory bowel disease, asthma, and sepsis, all of which have inflammation as a key component of their pathology. Additional investigations into the use of supplementation with fish oils in patients with neural injury, cancer, ocular diseases, and critical illness have recently been conducted. The most commonly reported adverse effects of fish oil supplements are a fishy aftertaste and gastrointestinal upset. When recommending an n-3 PUFA, clinicians should be aware of any possible adverse effect or drug interaction that, although not necessarily clinically significant, may occur, especially for patients who may be susceptible to increased bleeding (e.g., patients taking warfarin). CONCLUSION: The n-3 PUFAs have been shown to be efficacious in treating and preventing various diseases. The wide variation in dosages and formulations used in studies makes it difficult to recommend dosages for specific treatment goals.
Authors:
James W Fetterman; Martin M Zdanowicz
Related Documents :
15132735 - N-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored.
3651495 - Modification of fatty acid composition of membrane phospholipid in hepatocyte monolayer...
8784745 - Interference of free fatty acids from the hepatopancreas of mussels with the mouse bioa...
9720225 - Inhibition of icosanoid production in mc/9 mouse mast cells by n-3 polyunsaturated fatt...
19764065 - The ussing type chamber model to study the intestinal transport and modulation of speci...
363975 - An electron microscopic study of the location of peptidoglycan in group a and c strepto...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  66     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-18     Completed Date:  2009-09-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1169-79     Citation Subset:  IM    
Affiliation:
Department of Pharmaceutical Sciences, School of Pharmacy, South University, Savannah, GA 31406, USA. jfetterman@southuniversity.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents / administration & dosage,  adverse effects,  therapeutic use
Dietary Supplements
Docosahexaenoic Acids / administration & dosage*,  adverse effects,  therapeutic use
Dose-Response Relationship, Drug
Drug Interactions
Eicosapentaenoic Acid / administration & dosage*,  adverse effects,  therapeutic use
Fatty Acids, Omega-3 / administration & dosage*,  adverse effects,  therapeutic use
Fish Oils / administration & dosage,  adverse effects,  therapeutic use
Humans
Inflammation / drug therapy,  physiopathology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Fatty Acids, Omega-3; 0/Fish Oils; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CD44(high) memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
Next Document:  Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.